Department of Rheumatology, Univ. Lille, CHU Lille, Lille University Hospital, 59000, Lille, France.
Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France.
Arch Osteoporos. 2024 Mar 23;19(1):20. doi: 10.1007/s11657-024-01379-2.
We used data from a Fracture Liaison Service to compare the mean T-scores of obese and non-obese patients after a recent fragility fracture. After adjusting for age, sex, and diabetes mellitus, T-score values were significantly higher at all measurement sites in obese patients, with a mean difference of 1 SD.
This study aimed to compare the mean T-scores of obese and non-obese patients after recent fragility fractures.
Over a period of 5 and a half years, from January 2016 to May 2021, patients from a fracture liaison service were identified and their demographic characteristics, osteoporosis risk factors, BMD T-scores, and fracture sites were compared between obese (BMI ≥ 30 kg/m) and non-obese (19 kg/m < BMI < 30 kg/m) patients.
A total of 712 patients were included (80.1% women; mean age 73.8 ± 11.3 years). Sixteen % had type 2 diabetes mellitus and 80% had a major osteoporotic fracture (MOF). 135 patients were obese and 577 non-obese, with obese patients younger (p < 0.001) and more frequently female (p = 0.03). Obese patients presented with fewer hip fractures (10% vs. 21%, p = 0.003) and more proximal humerus fractures (16% vs. 7%, p < 0.001) than non-obese patients. After adjusting for age, sex, and diabetes mellitus, BMD T-score values were significantly higher at all measurement sites (lumbar spine, total hip, and femoral neck) in obese patients than in non-obese patients for all types of fractures, with a mean difference of 1 standard deviation (p < 0.001 for all comparisons). The same results were observed in the population limited to MOF.
Given the crucial role of BMD T-score in determining the need for anti-osteoporotic medication following fragility fractures, it is reasonable to question the existing T-score thresholds in obese patients.
本研究旨在比较近期脆性骨折后肥胖和非肥胖患者的平均 T 评分。
在 5 年半的时间里(2016 年 1 月至 2021 年 5 月),我们从骨折联络服务中确定了患者,并比较了肥胖(BMI≥30kg/m)和非肥胖(19kg/m<BMI<30kg/m)患者的人口统计学特征、骨质疏松症危险因素、BMD T 评分和骨折部位。
共纳入 712 例患者(80.1%为女性;平均年龄 73.8±11.3 岁)。16%患有 2 型糖尿病,80%患有主要骨质疏松性骨折(MOF)。135 例患者肥胖,577 例非肥胖,肥胖患者更年轻(p<0.001)且更常为女性(p=0.03)。与非肥胖患者相比,肥胖患者的髋部骨折(10% vs. 21%,p=0.003)和肱骨近端骨折(16% vs. 7%,p<0.001)较少。在调整年龄、性别和糖尿病后,与非肥胖患者相比,所有骨折类型的所有测量部位(腰椎、全髋和股骨颈)的 BMD T 评分值在肥胖患者中均显著更高,平均差异为 1 个标准差(所有比较的 p<0.001)。在仅限于 MOF 的人群中也观察到了相同的结果。
鉴于 BMD T 评分在确定脆性骨折后是否需要抗骨质疏松药物方面的重要作用,有理由质疑肥胖患者现有的 T 评分阈值。